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Natural killer(NK) cellshave been defined as non-MHC-restricted cytotoxiclym-
phocytes thatdo notrearrangeTCR genesor express cell surface CD3/Ti complexes,
but can be identified by the expression of the CD16 and/or Leu-19 antigens on the
cell surface membranes (1) . When activated with rIL-2, NK cells kill a broad range
of fresh uncultured tumor cell targets, including autologous tumor cells (2-4) . The
ability of rIL-2-activatedNK cells to lyse a variety of resistant tumor cell types in
vitro has led to the clinical trials of lymphokine-activated killer (LAK)t cell adop-
tive immunotherapy against neoplastic malignancies (5). The effect of rIL-2-activated
NK cellsonnormal hematopoiesis, in particular hematopoietic progenitor (HP) cells,
has been a controversial issue. Resting NK cells, although not inhibiting bone
marrow-derived erythroid burst-forming unit (BFU-E), moderately inhibitedbone
marrow granulocyte/macrophage CFU (CFU-GM) (day 14) and granulocyte,
erythroid, macrophage, megakaryocyteCFU(CFU-GEMM) (6-8) . ActivatedNK
cells have also been shown to inhibit bone marrow hematopoietic colony formation
(6, 9, 10) . Themechanisms bywhichNK cells regulate hematopoiesis remains largely
unknown, however, soluble factors such as IF andTNF may play a major role in
thephenomenon (9, 10) . In contrast to prior results withbone marrow, in the present
study, we have examined the effects of resting and rIL-2-activatedNK cells on pe-
ripheral blood-derivedHP cells in normal individualsandacutemyelogenousleukemia




PBMC from normal donors (Stanford Blood Center, Stanford,CA) andAML
patients induced into stable remissionby chemotherapy (StanfordUniversity Medical Center,
Palo Alto, CA) were isolated by Ficoll/Hypaque centrifugation . After plastic adherenceand
passage through nylon wool to remove monocytes and B cells, theLBD cells were isolated
by centrifugation through discontinuous gradients of Percoll (3). LBD cells were cultured
I Abbreviations used in this paper : AML, acute myelogenous leukemia ; BFU-E, erythroid burst-
forming unit ; CFU-GEMM, granulocyte, erythroid, macrophage, megakaryocyte CFU; CFU-GM,
granulocyte/macrophage CFU; HBD, high buoyant density; HP, hematopoietic progenitor ; LAK,
lymphokine-activated killer ; LBD, low buoyant density ; LGL, large granular lymphocytes ; PE,
phycoerythrin .
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in RPMI 1640 medium (M . A . Bioproducts, Walkersville, MD) containing 1 mM gluta-
mine, 100 ug/ml gentamicin (Gibco, Grand Island, NY), and FCS in the presence or ab-
sence of rIL-2 (Cetus Corp ., Emeryville, CA) .
Immunofluorescence and Flow Cytometry.
￿
Methods of immunofluorescence, flow cytometry,
and data analysis have been described previously (3) . Leu series antibodies were produced
by the Becton Dickinson Monoclonal Center, Inc ., Mountain View, CA.
Cytotozicity Assay.
￿
Cytotoxic activity was measured using a 4-h "Cr radioisotope release
assay (3) . Fresh unculturedAML tumor cells were obtained from AML patients during the
acute phase of the disease and were frozen in liquid nitrogen to be used as fresh autologous
leukemia cell targets .
Hematopoietic ClonogenicAssay.
￿
Cells were suspended in Iscove's modified Dulbeccds medium
with 15% FCS, .9% BSA (Armour Pharmaceutical Co., Tarrytown, NY), 50 ;1M 2-ME, 1%
penicillin/streptomycin, 1% glutamine, and 1.1% methycellulose . CFU-GM clonogenic assays
were performed using 15% placental-conditioned media as an exogenous source ofCSF BFU-E
andCFU-GEMM clonogenic assays contained I% Mo T cell-conditioned media as a source
of burst-promoting activity (kindly provided byDr. David Golde, UCLA Medical Center,
Los Angeles, CA) and 0.5 U/ml of purified human urinary erythropoietin . Cultures were
incubated in humidified 5% C02 at 37°C and microscopically scored for colony growth on
day 10 and 14, as previously described (11) .
Enrichment ofPeripheral BloodHP Cells.
￿
Peripheral blood HP cells (CD34') were enriched
from low buoyant density (LBD) cells using a magnetic bead depletion technique . LBD cells
were stained with saturating amounts of anti-Leu-1 (CD5), anti-Leu-2 (CD8), anti-Leu-3
(CD4), anti-Leu-4 (CD3), anti-Leu-M3, anti-Leu-11a (CD16), anti-Leu-12 (CD19), and anti-
Leu-16 (CD20) mAbs . The stained cells were washed, combined with goat anti-mouse Ig-
conjugated magnetic beads (Advanced Magnetics Inc ., Cambridge, MA), centrifuged at low
speed, and incubated as a pellet for 40min at 4°C . The pellet was then vortexed, underlayed
with 10 ml of Ficoll/Hypaque, and centrifuged at 1,500 rpm for 20 min . The cells recovered
at the interface (N5% ofthe total) were washed extensively and then applied to a plate magnet
(Advanced Magnetics, Inc .) to remove any residual magnetic beads . By this procedure,
CD34' were enriched to 65-68% purity.
Results and Discussion
Isolation and Characterization ofPeripheralBloodHP Cells.
￿
Human NK cells and HP
cells are characterized as large LBD cells (12-14) and thus can be coenriched on dis-
continuous density gradients of Percoll . PBMC depleted of monocytes and B cells
were separated into LBD and high buoyant density(HBD) cell populations on Per-
coll gradients (3) . As previously reported (3), LBD cells from Percoll gradients of
peripheral blood mononuclear cells are predominantly large granular lymphocytes
(LGL) consisting of 45-60'7o NK cells (Leu-19+, CD16+, CD3- ) and 35-50% T
cells (CD3 + ) . However, LBD cells from normal donors (n = 4) also contained
4-10% HP cells as identified by the mAb anti-HPCA-1, which recognizes the CD34
antigen . This represents a significant enrichment ofHP cells, since HP cells usually
make up <2% ofPBMC . Peripheral blood CD34' cells coexpressed HLA-DR an-
tigenand transferrin receptors but did not coexpress CD2, CD3, CD4, CD8, CD5,
CD16, or Leu-19 antigens . The phenotype of the peripheral blood HP cells is thus
consistent with the phenotype ofCD34' HP cells of the bonemarrow (15) . To verify
that the CD34+ cells generate in vitro hematopoietic colonies, peripheral blood
LBD cells were stained with anti-CD34 mAb, separated into CD34' and CD34-
populations using a FACS system, and cultured in methylcellulose colony assays.
CD34' LBD cells were similar to bone marrow HP cells and demonstrated a broad
spectrum of clonogenic capabilities (Table I) . The CD34- LBD cells showed essen-




Hematopoietic Colony Formation by Peripheral Blood CD34 * Cells
LBD cells were isolated from the peripheral blood of three normal donors and stained with
purified anti-HPCA 1 (CD34) mAb, followed by PE-conjugated rat anti-mouse IgGI mAb.
CD34* and CD34- cells were isolated to >97% purity using a FACS and cultured in
hematopoietic clonogenic assays . Results are presented as the mean colony number of dupli-
cate platings per 1 .5 x 10 5 cells plated .
Effects of rIL-2-activatedNK Cells on Autologous Peripheral BloodHP Cells.
￿
To deter-
mine the feasibility of using rIL-2-activatedNK cells to purge autologous HP cell
preparation of residual leukemia cells, it was first essential to investigate the effects
ofNK cells (resting and HL-2 activated) on the clonogenic colony formation capa-
bilities of autologous HP cells . Peripheral blood NK cells (CD16*) were purified
to homogeneity using a FACS and were incubated with and without rIL-2 for 24
h. Restingand rIL-2-activatedNK cells were then combined with either autologous
bone marrow cells or peripheral blood HP cell-enrichedpopulations and cocultured
in clonogenic methylcellulose colony formation assays . Consistent with prior reports
(8, 9), resting NK cells did not effect autologous bone marrow BFU-E ; however,
they moderately inhibited the formation ofCFU-GM (day 14) and strongly sup-
pressedCFU-GEMM (Fig . 1 A) . rIL-2-activated NK cells also inhibitedCFU-GM
FIGURE 1.
￿
The effects ofrestingand rIL-2-activated NK cells on
autologousHP cells . LBD cells were stainedwith FITC-conjugated
anti-Leu-11 (CD16) andNK cells (CDl6* ), and were isolated to
>97% purity using the FACS . (A) Autologous Ficoll-Hypaque-
sepatated bone marrow depleted ofplastic adherent cells, NK cells,
andT cells was used as asource ofHP cells. (B) Peripheral blood
HP cells (CD34*) were enriched from LBD cells using a mag-
netic bead depletion technique (65-68% CD34* by FACS anal-
ysis). Purified NK cells (CD16*) were incubated for 24h at 37°C
with orwithout100U/ml of rIL-2 (Cetus Corp.). Maximal levels
ofNK cell cytolysis canbe obtained in 24 h with 100U/ml HL-2
(3) . Resting(M)or rIL-2-activated(/)NK cells were combined
with enriched autologous HP cells at a ratio of 1:1 . Control cul-
tures ofenriched peripheral bloodHP cells were incubated without
NKcells .The results are presented as percent inhibition ofcolony
formationofcontrol cultures (average ofresults obtained with two
normal donors) . The control cultures contained 268 t 96 CFU-
GM (day 10), 130 t 40CFU-GM (day 14), 1,040 t 300BFU-E
(day 14), and 10 t 3 CFU-GEMM (day 14) per 1.5 x 10 5 plated
HP cells.
Donor FAGS sorted CFU-GM(10) CFU-GM(14) BFU-E CFU-GEMM
Colonies per 1.5 x 1175 cells
1 CD34* 600 260 2,400 18
CD34- 1 1 4 0
2 CD34* 532 248 2,148 ND
CD34- 1 .2 1 4 ND
3 CD34* 436 296 1,828 84
CD34- 0 0 0 050
￿
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FIGURE 2 .
￿
The effects of coculture ofNK cells and autolo-
gous HP cells. LBD cells obtained from normal donors were
incubated at 370C in the presence of 100 U/ml of rIL-2 . At
0, 1, and 3 d, theLBD cells were plated inhematopoietic clono-
genic assays (A) ; (0)CFU-GM (day 10), (11)CFU-GM (day
14), (/)BFU-E, (®)CFU-GEMM . Control cultures without
rIL-2 remained unchanged throughout the duration ofthe ex-
periment andcontained 36 t 6 CFU-GM (day 10), 48 t 7
CFU-GM (day 14),157 t 12 BFU-E, and8 t 2CFU-GEMM
per 1.5 x 10 5 plated cells. At each of these time points, the
LBD cells were also assayed for cytolytic activity (B) against
K562 ((J), Daudi (M), andColo 205 (/). Similar results were
obtained in five additional experiments.
(day 14), CFU-GEMM, and BFU-E (Fig. 1 A) . In contrast to the results obtained
when bone marrow was used as the source ofHP cells, NK cells (resting or rIL-2
activated) had no inhibitory effects on peripheral blood-derived HP cells (Fig. 1
B) . Thus, NK cells (resting or rIL-2 activated), although inhibiting hematopoietic
colony formation from the bone marrow, had no direct regulatory effects on HP
cells derived from theperipheral blood . The peripheral blood HP cells used in these
experimentswere enriched forCD34+ cells by depletion ofT cells, B cells, NK cells,
FIGURE 3 .
￿
Characterization ofLBD cells isolated
fromAML patients . Peripheral blood was obtained
from AML patients induced into stable remission
by inductive chemotherapy . (A) LBD cells were
stained with PE-conjugated anti-Leu-19 and FITC
conjugated anti-Leu-4 (CD3). NK cells (
￿
) were
defined as Leu-19' CD3- , while T cells (M)were
defined as Leu-19"~- , CD3' (1). HP cells (/)were
enumerated by staining with anti-HPCA 1 (CD34)
followed by a PE-conjugated rat anti-mouse IgGl
mAb . Results are presented as thepercentageofposi-
tive staining cells for each of the four individuals
studied . (B-E)LBD cells isolated from the fourAML
patient in remission were stained with PE-conjugated
anti-Leu-19 and FITC-conjugated anti-Leu-1 (CD5) .
Anti-CD5 wasused to identify and isolate T cells,
since antibodies againstCD3have been shown to ei-
ther inhibit or induceT cell-mediated cytotoxicity.
NK cells (Leu-19'/Leu-1 - ) were isolated to >97 To
purity using a FAGS, andwere assayed for cytotoxic
activity against Colo-205 (0) andtwo fresh uncul-
tured allogeneic leukemias (AO), beforeculture (open
symbols) and after overnight culture in 100 U/ml rIL-2
(solid symbols) .NAGLER ET AL.
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andmonocytes. In contrast, the bonemarrowpreparations used in these studieswere
not enriched for HP cells and represented a heterogeneous cell population. There-
fore, the NK cell-induced inhibition of bone marrow HP cells may be the result
ofindirect interactions ofNK cells with non-HP cells ofthebone marrow. Deglian-
toni et al. (8, 9)have suggestedthattheNKcell-mediatedinhibition ofbonemarrow
HPcells is manifested by the secretion ofNK cell-derived colony-inhibiting factors
generated from the interaction of NK cells with HLA-DR' bone marrow cells.
Since HP cells of the bone marrow express HLA-DR antigens, this study was un-
able todetermineifNKcells were directly interactingwithstem cells orotherHLA-
DR+ bone marrow cells. Further experimentation on the interaction ofautologous
NK cells with various cellular elements of the bone marrow is indeed required to
determine the mechanism ofinhibition ofbone marrow-derived HP cell colony for-
mation by NK cells.
The Effects ofExtended Coculture ofNK Cells and HP Cells.
￿
To directly investigate
the effects of activated NK cells on peripheral blood HP cells, LBD cells were in-
cubated at 37°C in the presence of rIL-2. At 0, 1, and 3 d, the cells were plated
for hematopoieticcolony growth and assayed for cytotoxic activity againstthe NK-
sensitive tumor line K562 (erythromyeloleukemia) and the NK-resistant cell lines
Daudi (B lymphoblastoid) and Colo-205 (colon carcinoma). Culturing LBD cells
for 3 dinthe presence ofrIL-2 hadno inhibitory effects on the formationofhemato-
poietic colonies (Fig. 2 A). Analysis ofthe cytotoxic activity ofthese cultures clearly
showed that the NK cells were substantially activated 24 h after culture with rIL-2
and reached maximallevels ofcytotoxic potential by 3 d (Fig. 2 B). Peripheral blood
HP cells cultured >3 d with or without NK cells showed decreases in hematopoietic
colony formation and viability.
NK Cells andPeripheral BloodHP Cellsfrom AML Patients.
￿
Studies were then per-
formed using PBMC derived from patients with AML induced by chemotherapy
into stable remission. LBD cells were isolated from AML remission patients and
examined for percentages ofNK cells, T cells, and CD34+ cells. These patients pos-
sessed normal percentages of NK cells and slightly elevated percentages ofCD34+
HP cells(Fig. 3 A). Atthetime ofstable remission, the LBDcells from these patients
contained no detectable leukemic blasts. The NK cells were functionally normal
and when activated overnight with rIL-2, demonstrated potent activated cytolysis
against fresh uncultured AML tumor cells as well as Colo-205 (Fig. 3 B-E). CD34+
HP cellsfrom theLBDcells ofAML remission patients demonstrated normal CFU-
GM, BFU-E, and CFU-GEMM hematopoietic colonies in vitro (data not shown).
rIL-2-activated NK cells from most AML patients were also capable of efficiently
lysing autologous AML tumor cells (Table II). In these studies, PBMC from AML
patients with varied percentages oftumor blasts were incubated in the presence of
rIL-2 for 10-14 d. NK cells were then purified from these cultures using a FRCS
andwere analyzed for cytolyticcapabilities against a panel oftumor cells including
autologous unculturedtumor and freshuncultured allogeneicAML tumors (Table
II). Inthreeofthe fourpatientsstudied, rIL-2-activatedNKcellswere verycytolytic
against autologous AML tumor as well as allogeneic AML tumor, Colo-205, and
K562. Patient AML-3 demonstrated strong levels ofcytolytic activity against Colo-
205, but showed only low levels of killing against autologous or allogeneic AML
tumor cells.52 NATURAL KILLER CELLS AND HEMATOPOIETIC PROGENITORS
TABLE II
Cytolysis of Autologous Tumor by rIL-Z-activated NK Cellsfrom AML Patients
PBMC were obtained from AML patients in acute phase: AML-1, 80% blasts; AML-2, 85%
blasts; AML-3, 72% blasts; AML-4, 50% blasts. LBD cells isolated from each of these pa-
tients were 190% leukemic blasts. A portion of these LBD cell preparations were frozen in
liquid nitrogen to be used as fresh uncultured autologous leukemia cells, while the remaining
LBD cells were cultured in 800 U/ml rIL-2 for 10-14 d. At this time, the cultures, which con-
sisted exclusively of normal lymphocytes, were stained with PE-conjugated anti-Leu-19 and
FITC-conjugated anti-Leu-4. NK cells (Leu-19', CD3- ) were isolated to >95% purity us-
ing a FACS and used as effector cells against various S1Cr labeled tumor cell targets, includ-
ing fresh uncultured autologous and allogeneic AML leukemia cells.
Recently, several investigators have reported that leukemia patients in remission
demonstrate elevated numbers ofperipheral blood HP cells afterinduction chemo-
therapy (16-18). The use ofautologous peripheral blood HP cells as an alternative
to autologous bone marrow transplantation has gained a great deal ofinterest, par-
ticularly with the preliminary reports that blood-derived HP cells can successively
reconstitute hematopoiesis aftermarrow-ablative radiotherapy (18-21). Amajor con-
sideration in autologous HP cell reconstitution is the inabilityto efficiently remove
residual tumorcells from the stem cellpreparations. Theuse ofperipheralblood-de-
rived HPcells, however, mayhave several favorable advantages including the ability
to obtain largenumbers ofHPcells through sequential leukapheresis that may con-
tain less tumor cell contamination than the bone marrow. Our results demonstrate
that the peripheralbloodofnormal donors, aswell asAML patients instable remis-
sion, have significant numbers of normal HP cells as well as NK cells that can be
induced to kill autologous leukemia cells without inhibiting the in vitro clonogenic
colony formation capabilities oftheperipheral blood HPcells. Based on these results,
we propose that rIL-2-activated NK cells may be successfully used to purge autolo-
gous peripheral blood HP cell preparations ofresidual leukemia cells in vitrobefore
reconstitution of the recipient. The capability ofrIL-2-activated NK cells to purge
autologous peripheral blood HP cell preparations ofresidual leukemia cells is de-
pendent upon the efficiency ofthe leukemic patients' activated NK cells to lyse au-
tologous tumorcells. Although themajorityoftheAMLpatients in this study showed





AML-1 6 73 69 69 21
3 76 58 55 10
1 .5 68 41 43 7
AML-2 6 90 60 67 32
3 65 32 53 27
1 .5 47 23 24 14
AML-3 6 85 67 - 22 11
3 61 50 - 14 5
1 .5 60 36 - 10 1
AML-4 6 92 65 - 52 - 76
3 90 53 - 40 - 63
1 .5 86 40 - 25 - 51NAGLER ET AL.
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potent activated NK cell lysis of autologous tumor, not all leukemia patients dis-
played the degree of autologous tumor killing required to achieve efficient tumor
cell purgingofperipheral bloodHP cell preparations. This does not representamajor
constraint, however, sinceleukemia cells can easily be frozen during the acute phase
of the patient's disease and subsequently assessed for susceptibility to cytolysis by
rIL-2-activated NK cells obtained from the peripheral blood at the time of remis-
sion. Moreover, this approach could potentially be combined with other recently
developed methods of leukemia therapy to increase the efficiency of these treatment
protocols. The results ofour studies also suggestthat it may be possible to effectively
treat some leukemia patients by activating endogenous NK cells to lyse autologous
tumor with in vivo rIL-2 therapy.
Summary
In the present study, we demonstrate that resting and rIL-2-activated NK cells
had no inhibitory effects on peripheral blood-derived hematopoieticprogenitor (HP)
cells. Peripheral blood HP cells were similar to bone marrow progenitors in pheno-
type and clonogenic colony formation capabilities. Peripheral blood HP cells could
be cocultured in vitro with rIL-2-activated autologous NK cells for 3 d without ad-
verse effects on the HP cells. Acute myelogenous leukemia patients in stable remis-
sion were shown to have normal percentages of NK cells and elevated percentages
ofperipheral blood HP cells. NK cells from most of these patients couldbe activated
with rIL-2 to lyse fresh uncultured tumor cells as well as autologous leukemia cells
without effecting the peripheral blood HP cells. These results suggest that rIL-2-
activated NK cells may be used to purge peripheral blood HP cell preparations of
residual tumor cells before hematopoietic reconstitution.
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